President & CEO
Mr. Kazu Kuramori is the President and CEO at GAIA BioMedicine, and he is responsible for the firm's entire operations, finance, and administrations. He started his career at the Ministry of Finance, and then he moved into the consulting space specializing in human resource management. Mr. Kuramori joined Ernst&Young transaction advisory service (EYTAS) in 2006. As a corporate finance advisor, he supported a broad spectrum of industries to complete M&As, corporate organizational reforms, and capital raising. After EYTAS, he joined Merrill Lynch and worked for the Global Private Equity division. Before joining GAIA BioMedicine, he was a board member of Noritsu Koki Co., Ltd., a Japan-based manufacturing firm, for four years. He was in charge of a wide swath of corporate functions, including corporate planning, business development, and M&As.
Mr. Kuramori holds a B.A. in intercultural studies from Kobe University. He earned his MBA from the University of Chicago Booth School of Business as a Wallman Scholar.
Chief Scientific & Technology Officer
Dr. Yoshikazu Yonemitsu is a professor at the R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University.
After working in the vascular surgery unit at Kyushu University Hospital, he served at the Gene Therapy Department of Imperial College London as a Wellcome Trust Fellow.
He specializes in oncology, gene and cell therapy, and cardiovascular medicine and helped establish GAIA BioMedicine in October 2015.
Dr. Yui Harada is an associate professor at the R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences of Kyushu University. He has been involved in the development of GAIA-102 from the very beginning. He specializes in oncology, immunology, and cellular therapy.